A slender tract of glycine residues is required for translocation of the VP2 protein N-terminal domain through the parvovirus MVM capsid channel to initiate infection

2013 ◽  
Vol 455 (1) ◽  
pp. 87-94 ◽  
Author(s):  
Milagros Castellanos ◽  
Rebeca Pérez ◽  
Alicia Rodríguez-Huete ◽  
Esther Grueso ◽  
José M. Almendral ◽  
...  

Very small residues at a glycine-rich tract in the capsid protein of the minute virus of mice are required to allow the translocation of a peptide segment through narrow pores in the viral capsid, which is needed for infection.

2014 ◽  
Vol 40 (01) ◽  
pp. 21-27
Author(s):  
Cho-Hua Wan ◽  
David J. Pintel ◽  
Lela K. Riley

Rat minute virus type 1 (RMV-1) was identified in laboratory rats. In this study, an ELISA using a recombinant capsid protein (rVP2) of RMV-1 was developed to diagnose RMV infections. The developed RMV-1 rVP2 ELISA exhibited a sensitivity of 97.5% and a specificity of 100%, and was more sensitive and specific in detecting RMV-1 infection than the ELISA using a recombinant minute virus of mice non-structural protein as antigen.


2000 ◽  
Vol 74 (23) ◽  
pp. 10892-10902 ◽  
Author(s):  
Beatriz Maroto ◽  
Juan C. Ramı́rez ◽  
José M. Almendral

ABSTRACT The core of the VP-1 and VP-2 proteins forming the T=1 icosahedral capsid of the prototype strain of the parvovirus minute virus of mice (MVMp) share amino acids sequence and a common three-dimensional structure; however, the roles of these polypeptides in the virus infection cycle differ. To gain insights into this paradox, the nature, distribution, and biological significance of MVMp particle phosphorylation was investigated. The VP-1 and VP-2 proteins isolated from purified empty capsids and from virions containing DNA harbored phosphoserine and phosphothreonine amino acids, which in two-dimensional tryptic analysis resulted in complex patterns reproducibly composed by more than 15 unevenly phosphorylated peptides. Whereas secondary protease digestions and comigration of most weak peptides in the fingerprints revealed common phosphorylation sites in the VP-1 and VP-2 subunits assembled in capsids, the major tryptic phosphopeptides were remarkably characteristic of either polypeptide. The VP-2-specific peptide named B, containing the bulk of the32P label of the MVMp particle in the form of phosphoserine, was mapped to the structurally unordered N-terminal domain of this polypeptide. Mutations in any or all four serine residues present in peptide B showed that the VP-2 N-terminal domain is phosphorylated at multiple sites, even though none of them was essential for capsid assembly or virus formation. Chromatographic analysis of purified wild-type (wt) and mutant peptide B digested with a panel of specific proteases allowed us to identify the VP-2 residues Ser-2, Ser-6, and Ser-10 as the main phosphate acceptors for MVMp capsid during the natural viral infection. Phosphorylation at VP-2 N-terminal serines was not necessary for the externalization of this domain outside of the capsid shell in particles containing DNA. However, the plaque-forming capacity and plaque size of VP-2 N-terminal phosphorylation mutants were severely reduced, with the evolutionarily conserved Ser-2 determining most of the phenotypic effect. In addition, the phosphorylated amino acids were not required for infection initiation or for nuclear translocation of the expressed structural proteins, and thus a role at a late stage of MVMp life cycle is proposed. This study illustrates the complexity of posttranslational modification of icosahedral viral capsids and underscores phosphorylation as a versatile mechanism to modulate the biological functions of their protein subunits.


Virology ◽  
2015 ◽  
Vol 476 ◽  
pp. 61-71 ◽  
Author(s):  
Sunil K. Tewary ◽  
Lingfei Liang ◽  
Zihan Lin ◽  
Annie Lynn ◽  
Susan F. Cotmore ◽  
...  

2017 ◽  
Vol 91 (9) ◽  
Author(s):  
Weifeng Wang ◽  
Jing Zhou ◽  
Upul D. Halambage ◽  
Kellie A. Jurado ◽  
Augusta V. Jamin ◽  
...  

ABSTRACT The human immunodeficiency virus type 1 (HIV-1) capsid protein is an attractive therapeutic target, owing to its multifunctionality in virus replication and the high fitness cost of amino acid substitutions in capsids to HIV-1 infectivity. To date, small-molecule inhibitors have been identified that inhibit HIV-1 capsid assembly and/or impair its function in target cells. Here, we describe the mechanism of action of the previously reported capsid-targeting HIV-1 inhibitor, Boehringer-Ingelheim compound 1 (C1). We show that C1 acts during HIV-1 maturation to prevent assembly of a mature viral capsid. However, unlike the maturation inhibitor bevirimat, C1 did not significantly affect the kinetics or fidelity of Gag processing. HIV-1 particles produced in the presence of C1 contained unstable capsids that lacked associated electron density and exhibited impairments in early postentry stages of infection, most notably reverse transcription. C1 inhibited assembly of recombinant HIV-1 CA in vitro and induced aberrant cross-links in mutant HIV-1 particles capable of spontaneous intersubunit disulfide bonds at the interhexamer interface in the capsid lattice. Resistance to C1 was conferred by a single amino acid substitution within the compound-binding site in the N-terminal domain of the CA protein. Our results demonstrate that the binding site for C1 represents a new pharmacological vulnerability in the capsid assembly stage of the HIV-1 life cycle. IMPORTANCE The HIV-1 capsid protein is an attractive but unexploited target for clinical drug development. Prior studies have identified HIV-1 capsid-targeting compounds that display different mechanisms of action, which in part reflects the requirement for capsid function at both the efferent and afferent phases of viral replication. Here, we show that one such compound, compound 1, interferes with assembly of the conical viral capsid during virion maturation and results in perturbations at a specific protein-protein interface in the capsid lattice. We also identify and characterize a mutation in the capsid protein that confers resistance to the inhibitor. This study reveals a novel mechanism by which a capsid-targeting small molecule can inhibit HIV-1 replication.


1986 ◽  
Vol 59 (3) ◽  
pp. 564-573 ◽  
Author(s):  
C V Jongeneel ◽  
R Sahli ◽  
G K McMaster ◽  
B Hirt

Sign in / Sign up

Export Citation Format

Share Document